Novavax coronavirus vaccine shows 89% efficacy in UK trials

  29 January 2021    Read: 974
Novavax coronavirus vaccine shows 89% efficacy in UK trials

A new coronavirus vaccine has been shown to be 89.3% effective in large-scale UK trials, AzVision.az reports citing BBC.

The Novavax jab is the first to show it is effective against the new variant of the virus discovered in the UK, the BBC's medical editor Fergus Walsh said.

The PM welcomed the "good news" and said the UK's medicines regulator would now assess the vaccine.

The UK has secured 60 million doses of the jab, which will be made in Stockton-on-Tees.

The doses are expected to be delivered in the second half of this year, if approved for use by the Medicines and Healthcare Products Regulatory Agency (MHRA), the government said.

The UK has so far approved three coronavirus vaccines for emergency use - one from Oxford University and AstraZeneca, another by Pfizer and BioNTech, and a third from drug firm Moderna.

The Novavax jab was shown to be 89.3% effective at preventing Covid-19 in participants in its Phase 3 clinical trial in the UK, which enrolled more than 15,000 people aged between 18-84, of whom 27% were older than 65, Novavax said.

In the South African part of the trial, where most of the cases were the South African variant of the virus, the vaccine was 60% effective among those without HIV.


More about: UK   coronavirus   vaccine  


News Line